title: Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma.
abstract: Multiple myeloma is a malignancy of B cells characterized by accumulation of abnormal plasma cells in the bone marrow. In the past 20 years, the use of high-dose therapies and novel agents has resulted in significant and meaningful improvements in survival. Autologous stem cell transplantation (auto-SCT) following a high-dose melphalan-conditioning regimen represents the standard of care for younger patients as well as older patients with a good performance status. A number of strategies have been proposed to improve the outcome of auto-SCTs, including the incorporation of new agents such as thalidomide, lenalidomide, and bortezomib into the induction regimen administered before auto-SCT; the administration of maintenance therapy after auto-SCT; the incorporation of novel agents into chemotherapeutic regimens after transplantation as consolidation therapy; and the use of reduced-intensity allogeneic transplantation after an initial autograft. Although these approaches have demonstrated some success in improving responses after auto-SCT, none of these strategies are curative. An additional strategy to improve outcomes after auto-SCT is to enhance the immediate pretransplant conditioning regimens by either increasing the dose of melphalan or by incorporating novel agents, such as busulfan. This literature review focuses on the efficacy and safety of busulfan-based conditioning regimens for auto-SCT in patients with multiple myeloma.
authors: Princess Margaret Hospital, Division of Medical Oncology and Hematology, Toronto, Ontario, Canada. donna.reece@uhn.ca
authors: Donna
authors: D
authors: Reece
authors: Kevin
authors: K
authors: Song
authors: Richard
authors: R
authors: LeBlanc
authors: Khalid
authors: K
authors: Mezzi
authors: Ade
authors: A
authors: Olujohungbe
authors: Darrell
authors: D
authors: White
authors: Faraz
authors: F
authors: Zaman
authors: Andrew
authors: A
authors: Belch
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D064592:Autografts; D002066:Busulfan / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage*; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D039781:PubMed; D033581:Stem Cell Transplantation / Q000379:methods*; D019172:Transplantation Conditioning; D016896:Treatment Outcome
chemical_list: D002066:Busulfan; D008558:Melphalan
keywords: Busulfan; Conditioning regimens; Hematopoietic stem cell transplantation; Melphalan; Multiple myeloma
references: Bone Marrow Transplant. 1998 Jan;21(2):141-5
references: 9489630
references: Pediatrics. 2010 Apr;125(4):e925-30
references: 20351005
references: N Engl J Med. 2012 May 10;366(19):1782-91
references: 22571202
references: J Clin Oncol. 1992 Oct;10(10):1569-73
references: 1403036
references: Blood. 2010 Jan 7;115(1):32-7
references: 19884643
references: Blood. 2008 Nov 15;112(10):4017-23
references: 18669875
references: Blood. 2010 Feb 11;115(6):1113-20
references: 19880501
references: Bone Marrow Transplant. 2001 Apr;27(8):801-7
references: 11477436
references: Exp Hematol. 2009 May;37(5):593-603
references: 19375650
references: Br J Haematol. 2002 Jun;117(3):605-12
references: 12028028
references: Bone Marrow Transplant. 1997 Oct;20(8):653-6
references: 9383228
references: J Clin Oncol. 2011 Apr 20;29(12):1627-33
references: 21402611
references: Bone Marrow Transplant. 2003 Sep;32(6):593-9
references: 12953132
references: J Clin Oncol. 2010 May 20;28(15):2612-24
references: 20385994
references: Blood Rev. 2007 Nov;21(6):301-14
references: 17761373
references: Leuk Res. 2007 Aug;31(8):1069-75
references: 17070906
references: Bone Marrow Transplant. 2001 May;27(9):925-31
references: 11436102
references: Haematologica. 2000 Jan;85(1):52-8
references: 10629592
references: J Clin Oncol. 1996 May;14(5):1447-56
references: 8622058
references: Br J Haematol. 1995 Oct;91(2):380-6
references: 8547079
references: Curr Med Chem. 2011;18(34):5172-3
references: 22172024
references: Haematologica. 2010 Nov;95(11):1913-20
references: 20663944
references: Bone Marrow Transplant. 2000 Nov;26(10):1045-9
references: 11108301
references: Blood. 2000 Apr 1;95(7):2234-9
references: 10733490
references: Blood. 2006 Nov 15;108(10):3289-94
references: 16873668
references: Haematologica. 2007 Oct;92(10):1399-406
references: 18024376
references: N Engl J Med. 2012 May 10;366(19):1770-81
references: 22571201
references: Bone Marrow Transplant. 1993 Feb;11(2):139-46
references: 8435663
references: Bone Marrow Transplant. 2009 Aug;44(3):157-61
references: 19204716
references: Blood. 2012 Mar 29;119(13):3003-15
references: 22271445
references: J Clin Oncol. 1997 Feb;15(2):667-73
references: 9053492
references: Blood. 1993 Oct 15;82(8):2324-8
references: 8104539
references: Hematol J. 2004;5(2):118-22
references: 15048061
references: Leuk Lymphoma. 2002 Jan;43(1):67-74
references: 11908738
references: Bone Marrow Transplant. 2001 Apr;27(8):821-8
references: 11477439
references: Biol Blood Marrow Transplant. 2011 Mar;17(3):412-20
references: 20674757
references: Am J Hematol. 2003 Jul;73(3):169-75
references: 12827653
references: Cancer. 2004 Jun 15;100(12):2607-12
references: 15197803
references: Mayo Clin Proc. 2010 Mar;85(3):225-30
references: 20194150
references: Leuk Lymphoma. 2009 Feb;50(2):216-22
references: 19197734
references: Acta Haematol. 2006;115(1-2):9-14
references: 16424643
references: J Clin Oncol. 1998 Feb;16(2):593-602
references: 9469347
references: Br J Haematol. 2004 Mar;124(6):769-76
references: 15009065
references: Lancet. 2008 May 17;371(9625):1642-4
references: 18486726
references: J Clin Oncol. 2007 Jun 10;25(17):2434-41
references: 17485707
references: Cancer. 2006 May 15;106(10):2171-80
references: 16598756
references: Blood. 2011 Jul 21;118(3):529-34
references: 21482708